Axcella to Present at the 28th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass.--()--Axcella, a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the 28th Annual Piper Jaffray Healthcare Conference in New York, N.Y. The presentation will take place November 30, 2016, at 3:10 p.m. EST.

About Axcella

Axcella is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has identified more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in metabolic (liver, muscle) and neurodegenerative conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.

Contacts

Media Contact
Ten Bridge Communications
Dan Quinn, 781-475-7974
dan@tenbridgecommunications.com
or
Company Contact
Christine Lafontant, 857-320-2250
clafontant@axcellahealth.com

Release Summary

Axcella’s CEO, Robert Connelly, will present a company overview at the 28th Annual Piper Jaffray Healthcare Conference in New York, N.Y. on November 30, 2016, at 3:10 p.m. EST.

Contacts

Media Contact
Ten Bridge Communications
Dan Quinn, 781-475-7974
dan@tenbridgecommunications.com
or
Company Contact
Christine Lafontant, 857-320-2250
clafontant@axcellahealth.com